Sheet <u>1</u> of <u>2</u>

		<u>J</u>											
FORM		1449		PARTMENT OF COMMERCE AND TRADEMARK OFFICE		ATTY. DOCKET NO.: OC01617K1				APPLICATION NO.: 10/776, 988			
RADE	AREL	201		ON DISCLOSURE STATEMENT			APPLICANT:						
	IINE	JKIV			EMENI		inzi :	et al					
1			BY APPLIC	Timothy J. Guzi et al.									
	(Use several sheets if necessary)						FILING DATE:			GROUP L "			
<u> </u>		<u> </u>	,										
<u></u> .			•		ENT DOCUM								
EXAM			DOCUMENT	T DATE NA		AME CLASS		SUB- FILING DATE I					
INIT	12	AA	NUMBER 5 571 912	11/05/1996	Rühter et al.		<del></del>		CLASS		APPROPRIATE		
<del></del>	Ψ_	AB	5,571,813	02/11/1997	· .	er et al. er et al.	+	+	+-	+-	<del> </del>		
<del></del>		AC	5,602,136 5,602,137	02/11/1997		er et al. er et al.		+-	+	<del> </del>	<del> </del>		
	┿	AD	5,688,949	11/18/1997	<del></del>		+	+	+	$\vdash$	<del> </del>		
<u> </u>	+-	AE	5,707,997	01/13/1998		e et al. et al.	+	┼	<del> </del>	<b>├</b> ─			
<b>——</b>	+	AF	5,919,815	07/06/1999		ey et al.		<del> </del>	┼	├	<del></del>		
	+	AG	6,040,321	03/21/2000		et al.	+-	<del> </del>	├	<del> </del>	<del>                                     </del>		
	+	AH					+	<u> </u>	+		<u> </u>		
<u> </u>	+-	AI	6,107,305	08/22/2000	<del></del>	et al.	+	├	<del> </del>		<del> </del>		
	+,	<del></del>	6,191,131	02/20/2001		et al.		├	ļ	$\vdash$			
$\vdash \vdash \vdash \vdash$	$\Psi$	AJ	6,262,096 6,413,974			et al.		<u> </u>	1	$\vdash$			
<b>├</b> ─-		AK	<del></del>	07/02/2002		nt <i>et al.</i>	_		ــــــــــــــــــــــــــــــــــــــ	<b> </b>	L		
			F	FOREIGN P.	ATENT DOC	UMENTS							
			DOCUMENT	DATE	COUNTRY		CL	ASS	SU	3-	TRANSI	NOITA	
1			NUMBER						CLA	ASS	YES	NO	
	7	AL	DE 102 23 917 A1	11/12/2003	Gerr	many	1						
	7	AM	EP 0 628 559	04/03/2002		оре	1						
	1	AN	EP 1 334 973	08/13/2003		оре							
		AO	WO 02/22610	03/21/2002		CT		•					
		AP	WO 02/40485	05/23/2002	P	CT							
		AQ	WO 02/50079	06/27/2002	· P(	CT .			<b></b>			l	
	1/	AR	WO 03/091256 A1	11/06/2003	P	CT						i	
	V	AS	WO 95/35298	12/28/1995	P	CT							
		OTI	HER DOCUMENT	S (Including	Author Title	Date Per	tinar	of De	200	Et.	c )		
<u> </u>		IAT		ion of Cyclin-D	ependent Kina	ses by Purine	Apala	IL F G	yes	, <u>L</u> [	Biochon		
V			(1994), 224: 771-78		ependent Kinas	ses by Fullie /	- Indic	yues	,	1. J.	Biochen	'	
-		ΑŪ	Kim et al., "Discover		zole Inhibitors o	of Cyclin-Dene	nden	Kins	150 2	Syr	thesis '	X-rav	
1 1			Crystallographic Ana	dysis and Biol	onical Activities	" Journal of M	ledic:	al Chi	emisi	in (	20021 4	5·	
	•		3905-3927.	,0.0, 00 2.0.	09.00.7.0	, 000, 110, 01, 111	00.00		,,,,,,,,,,	·	,	•	
		ΑV											
			Complex with CDK2, Enzyme Selectivity, and Cellular Effects", J. Med. Chem. (2003), 46(2): 222-										
			236.										
		AW	Novinson et al., "Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-										
			a]pyrimidines", J. Med. Chem. (1977), <b>20</b> (2): 296-299.										
		AX	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent										
1	1		Kinase Inhibitor, in Patients with Refractory Neoplasms", Journal of Clinical Oncology (September										
		Ĺ	1998), 16(9): 2986-2999.										
	AY Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of								or of				
		<u></u>	the Cyclin-Depender	y Kinases CD	C2, CDK2 and (	CDK5", <i>Eµr. J.</i>	Bioc	hem.	(199	7), 2	43:527-	536.	
EXAM	IINE	₹	/Y) / T/I	'/	DATE C	ONSIDERED		/					
Jon 11/01 6/17/07													
15×1	<u>/ _</u>	<u> </u>	7/1/4			6/17	<i>I</i> .	•					
EXA	MINE	K: In	itial if reference consi	dered, whethe	r or not citation	is in conforma	ince y	with N	<b>NPEF</b>	609	r; Draw	line	
		IUON I	if not in conformat/ce	and not consid	ierea. Include (	copy of this for	ın Wi	ın ne	XT CO	mmu	nication	ιο	
applic	applicant.												

FORM PTO-1	449		ATTY. DOCKET NO.:	APPLICATION NO.:							
		PATENT AND TRADEMARK OFFICE	OC01617K1	10/776,988							
INFO	RM	ATION DISCLOSURE STATEMENT	APPLICANT: Timothy J. Guzi et al.								
ĺ	71.1	se several sheets if necessary)	FILING DATE:	GROUP:							
	(0.		02/22/2004	100							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
	AZ Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various										
		Antineoplastic Agents: The Importance of Sequence of Administration", Cancer Research (August 15, 1997), 57: 3375-3380.									
	BA Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensir										
	II Receptor Antagonists: Pyrazolo[1,5-α]pyrimidine Derivatives", Chem. Pharm. Bull. (1999), 47(7): 928-938.										
	BB Translation of WO 03/91256, A Rising Sun Communications Ltd. Translation Product, (1-62)										
	BC Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted										
	Pyrazolo[1,5-a]pyrimidines.", Chem. Pharm. Bull (1962), 10: 620-626.										
	BD Cai et al., "5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, Systemically										
1 1	Active and Broad Spectrum Antagonists for NMDA/glycine, AMPA, and Kainate Receptors", J.										
ļ	Med. Chem. (1997), 40:3679-3686.  BE Bruce L. Finkelstein. "Regioselective Lithiation and Reaction of [1,2,4]Triazolo[1,5-a]pyridine and										
	BE Bruce L. Finkelstein, "Regioselective Lithiation and Reaction of [1,2,4]Triazolo[1,5-a]pyridine and Pyrazolo[1,5-a]pyridine", J. Org. Chem., (1992), 57: 5538-5540.										
	BF Ongkeko et al., "Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage",										
		Journal of Cell Science (1995), 108: 2897-2904.									
[E	BG Shiota et al., "Regioselective Reactions of Organozinc Reagents with 2,4-Dichloroquinoline and										
ļ	5,7-Dichloropyrazolo[1,5-a]pyrimidine", J. Org. Chem. (1999), 64: 453-457.										
	BH Novinson et al., "Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo-αs-										
	BI	triazines <sup>1</sup> ", Journal of Medicinal Chemistry, (1976)	), <b>19</b> (4): 517-520.								
EXAMINER	ы	1/1 / 2 IDATE C	ONSOEDED								
1 10m/11/2 6/17/67											
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line											
through citation if not in conformance and not considered. Include copy of this form with next communication to											
applicant.											